Shots:

• The P-lb/ll GO29365 study involves assessing of Polivy (polatuzumab vedotin) + BR vs BR as monthx. in 106 patients with r/r DLBCL who are not eligible for stem cell transplant
• Result: @48.9mos. CR rate (42.5% vs 17.5%); m-PFS (9.2 vs 3.7 mos.); m-OS (12.4 vs 4.7 mos.); New data from the extension cohort- in 37 patients with 2L DLBCL showed Polivy + BR is effective across a broad range of patients and showed m-PFS (6.6 mos.); median OS (12.5 mos.)
• Sub-group analyses showed that combination was effective in different patient populations with the results from the pooled Polivy + BR arms achieving an m-OS of 7.6mos. in primary refractory patients and 32.0mos. in non-primary refractory patients

 ­ Ref: GlobeNewswire | Image: Roche